ホーム › 転移性癌 › マサチューセッツ州 › Boston
Boston、MAにおける転移性癌の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する63件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
被験者募集中第2相
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Dana Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- Dana-Farber Cancer Institute, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
被験者募集中第3相
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
被験者募集中第1/2相
- Dana Farber Cancer Institute., Boston
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
被験者募集中第1/2相
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
被験者募集中第1相
- Mass General Cancer Center, Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- Massachusetts General Hospital, Boston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
被験者募集中第3相
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
被験者募集中第1/2相
- Massachusetts General Hospital - Main Campus, Boston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
被験者募集中第1/2相
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Boston Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Boston
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital (MG), Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Boston
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
被験者募集中第1相
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
A Study of PYX-201 in Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
被験者募集中第1相
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #10, Boston
- Exelixis Clinical Site #11, Boston
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
被験者募集中第1相
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
被験者募集中第1相
- Massachusetts General Hospital, Boston
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
被験者募集中第3相
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
被験者募集中第2相
- I-Mab Site 1002, Boston
Remote Monitoring and Symptom Management Digital Application
被験者募集中
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- Massachusetts General Hospital, Boston
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
被験者募集中第2/3相
- Dana-Farber Cancer Institute, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
被験者募集中第2/3相
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
被験者募集中第2/3相
- Massachusetts General Hospital, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
被験者募集中第1相
- Dana-Farber Cancer Institute, Boston
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
被験者募集中
- Massachusetts General Hospital, Boston
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
被験者募集中第1相
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Mass General Hospital, Boston
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
被験者募集中第1相
- Massachusetts General Hospital, Boston
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
被験者募集中第3相
- Dana-Farber Cancer Institute, Boston
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
被験者募集中観察研究
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
被験者募集中健康なボランティア歓迎
- Dana Farber Cancer Institute, Boston
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
- Seattle, WA39件の研究
Bostonにおける他の研究
- 乳がん111件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）86件の研究
- 大腸癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
- 膵臓がん43件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。